1. Home
  2. NPO vs DNTH Comparison

NPO vs DNTH Comparison

Compare NPO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enpro Inc.

NPO

Enpro Inc.

HOLD

Current Price

$306.90

Market Cap

6.7B

Sector

Industrials

ML Signal

HOLD

Logo Dianthus Therapeutics Inc.

DNTH

Dianthus Therapeutics Inc.

HOLD

Current Price

$90.65

Market Cap

4.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NPO
DNTH
Founded
2002
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
4.6B
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
NPO
DNTH
Price
$306.90
$90.65
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$278.33
$121.00
AVG Volume (30 Days)
203.0K
425.6K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
0.46%
N/A
EPS Growth
N/A
N/A
EPS
1.29
N/A
Revenue
$1,532,000,000.00
$2,036,000.00
Revenue This Year
$12.31
N/A
Revenue Next Year
$6.39
$29.48
P/E Ratio
$243.54
N/A
Revenue Growth
16.98
N/A
52 Week Low
$178.22
$16.77
52 Week High
$326.98
$96.50

Technical Indicators

Market Signals
Indicator
NPO
DNTH
Relative Strength Index (RSI) 53.47 59.23
Support Level $294.00 $81.16
Resistance Level $326.98 $96.50
Average True Range (ATR) 10.08 4.45
MACD -1.27 0.25
Stochastic Oscillator 38.17 85.05

Price Performance

Historical Comparison
NPO
DNTH

About NPO Enpro Inc.

Enpro Inc formerly EnPro Industries Inc is a United States-based company that designs, develops, manufactures, and markets proprietary engineered industrial products. The company operates through two segments: Sealing Technologies, which derives maximum revenue, manufactures and markets sealing products, wheel-end components & systems; and Advanced Surface Technologies, which manufactures wafer processing sub-systems, thin-film coatings, optical filters, and other services like cleaning, coating, testing, and refurbishment. Its geographical segments are the United States, Europe, and other foreign countries.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

Share on Social Networks: